
Methods:We defined a cohort of Oregon residents ≥18 years old with HCV infection enrolled in Medicaid at least one year during 2009-2013. By matching this cohort to state vital records and the state cancer registry, we estimated the incidence of HCV-related death and HCC during the same time period and used a Cox proportional hazards model for each of these outcomes to evaluate the impact of demographic characteristics.
Results: We identified 11,790 patients with HCV infection. The majority of the patients were white (84%), male (46%), and born between 1945 and 1965 (61%). We identified 474 (4.0%) HCV-related deaths and 156 (1.3%) cases of HCC, corresponding to incidence density rates of 29.8 per 1000 person-years (py) (95% Confidence interval [CI]: 22.7,36.9) and 6.3 per 1000 py (95% CI:5.3, 7.2), respectively. For mortality, the Cox proportional hazards model identified the chief risk factors as age and Asian/Pacific Islander race, while female gender and urban residence were protective. For HCC, the significant risk factors were age and gender.
Conclusion: We quantified the burden of HCV-related morbidity and mortality in Oregon. We also found that Asian/Pacific Islander had the highest risk of death among Medicaid patients with HCV in Oregon. Using state-specific estimates for mortality and HCC, researchers can develop more accurate estimates of the potential cost-effectiveness of using newer regimens to treat Oregon Medicaid patients.
Demographic characteristics associated with HCV-related death & Hepatocellular carcinoma Oregon Medicaid HCV cohort, 2009-2013 (n=11,790) |
|||
|
Hazard Ratio |
p-value |
95% CI |
DEATH |
|
|
|
Age* |
1.14 |
<0.001 |
1.10, 1.19 |
Gender |
|
|
|
Female |
0.51 |
<0.001 |
0.42, 0.61 |
Male |
- |
- |
- |
Race |
|
|
|
Asian/Pacific Islander |
1.66 |
0.02 |
1.08, 2.55 |
Other races combined |
0.96 |
0.79 |
0.73,1.27 |
White |
- |
- |
- |
Residence |
|
|
|
Urban |
0.80 |
0.02 |
0.66, 0.96 |
Rural |
- |
- |
- |
HEPATOCELLULAR CARCINOMA |
|
||
Age* |
1.28 |
<0.001 |
1.19, 1.38 |
Gender |
|
|
|
Female |
0.27 |
<0.001 |
0.17,0.41 |
Male |
- |
- |
- |
CI, Confidence interval |

K. Jindai,
None
D. Hartung, None
A. Zaman, Gilead: Investigator , Research grant
Bristol Myers Squibb: Consultant , Consulting fee
A. Thomas, None